YM116 is an orally active and competitive CYP17A1 (17,20-lyase) inhibitor ( K i : 0.38 nM). YM116 reduces the synthesis of adrenal androgens by preferentially inhibiting C17-20 lyase activity. YM116 decreases the serum testosterone concentration, reduces dehydroepiandrosterone sulfate levels and decreases prostatic weights.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Endocrinology | Products > Signaling Pathways > Cytochrome P450
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.